These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33675302)

  • 1. Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program.
    McCune JS; Punt AM; Yeh RF; Dupuis LL; Kweekel DM; Franssen EJF; Ritchie JC; van Maarseveen E; Huitema ADR
    Ther Drug Monit; 2021 Oct; 43(5):657-663. PubMed ID: 33675302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Busulfan Interlaboratory Proficiency Testing Program Revealed Worldwide Errors in Drug Quantitation and Dose Recommendations.
    Kweekel DM; McCune JS; Punt AM; van Luin M; Franssen EJF
    Ther Drug Monit; 2023 Dec; 45(6):760-765. PubMed ID: 37199431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.
    Burger D; Teulen M; Eerland J; Harteveld A; Aarnoutse R; Touw D
    Ther Drug Monit; 2011 Apr; 33(2):239-43. PubMed ID: 21383652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.
    Choong E; Uppugunduri CRS; Marino D; Kuntzinger M; Doffey-Lazeyras F; Lo Piccolo R; Chalandon Y; Peters C; Daali Y; Ansari M
    Ther Drug Monit; 2018 Feb; 40(1):84-92. PubMed ID: 29189665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation.
    Abdel-Rahman SM; Casey KL; Garg U; Dalal J
    Pediatr Transplant; 2016 May; 20(3):443-8. PubMed ID: 26854326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
    Poinsignon V; Faivre L; Nguyen L; Neven B; Broutin S; Moshous D; Bourget P; Dufour C; Dalle JH; Galambrun C; Devictor B; Kemmel V; De Berranger E; Gandemer V; Vannier JP; Jubert C; Bondu S; Mir O; Petain A; Vassal G; Paci A
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28603. PubMed ID: 32706505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test-Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients.
    Dunlap TC; Weiner DL; Kemper RM; Kardouh M; DeVane SC; Symonds A; Shaw JR; Armistead PM; Ptachcinski JR; Crona DJ
    J Clin Pharmacol; 2023 Sep; 63(9):1026-1035. PubMed ID: 37122163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation.
    Slattery JT; Risler LJ
    Ther Drug Monit; 1998 Oct; 20(5):543-9. PubMed ID: 9780133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate Prediction of Initial Busulfan Exposure Using a Test Dose With 2- and 6-Hour Blood Sampling in Adult Patients Receiving a Twice-Daily Intravenous Busulfan-Based Conditioning Regimen.
    Huang J; Li Z; Liang W; Chen B; Hu J; Yang W
    J Clin Pharmacol; 2019 May; 59(5):638-645. PubMed ID: 30512187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
    Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
    Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid & sensitive liquid chromatography- tandem mass spectrometry method for the quantitation of busulfan levels in plasma & application for routine therapeutic monitoring in haematopoietic stem cell transplantation.
    Desire S; Mohanan EP; George B; Mathews V; Chandy M; Srivastava A; Balasubramanian P
    Indian J Med Res; 2013 Apr; 137(4):777-84. PubMed ID: 23703347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.
    McCune JS; Bemer MJ; Barrett JS; Scott Baker K; Gamis AS; Holford NH
    Clin Cancer Res; 2014 Feb; 20(3):754-63. PubMed ID: 24218510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
    Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
    Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
    Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Analysis of Busulfan in Japanese Pediatric and Adult HCT Patients.
    Kawazoe A; Funaki T; Kim S
    J Clin Pharmacol; 2018 Sep; 58(9):1196-1204. PubMed ID: 29663421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
    Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients.
    Yeh RF; Pawlikowski MA; Blough DK; McDonald GB; O'Donnell PV; Rezvani A; Deeg HJ; McCune JS
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):265-72. PubMed ID: 21736869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
    Perkins JB; Kim J; Anasetti C; Fernandez HF; Perez LE; Ayala E; Kharfan-Dabaja MA; Tomblyn MR; Sullivan DM; Pidala JA; Field TL
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1099-107. PubMed ID: 22198540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization.
    Effting C; de Moraes Arantes A; Queiroz Labre LV; Carneiro WJ; de Oliveira Neto JR; Bariani C; Rodrigues CR; Rodrigues AR; Cunha LC
    Ther Drug Monit; 2015 Feb; 37(1):66-70. PubMed ID: 25588069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation.
    de Castro FA; Lanchote VL; Voltarelli JC; Colturato VA; Simões BP
    J Clin Pharmacol; 2013 Nov; 53(11):1205-11. PubMed ID: 23955479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.